Resources
Did you mean
biotechnology (6,699 results), Sinovac Biotech Ltd. (17 results), biotechnology company (10 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ImClone: Non-Justifiable Scientific Downgrades Refuted
- The recent findings of clinical trials on the safety and efficacy of ImClone Systems' IMCL Erbitux in regard to advanced colo-rectal cancer refute the frivolous claim/downgrade by Friedman, Billings Ramsey & Co. analyst Jim Reddoch. The above mentioned analysts, who have absolutely no medical training in evaluating clinical trials, cited...
- External links 2008-08-06
- Be Selective with Medical Device Companies
- Zacks.com submits: With earnings season beginning to wind down in the medical devices and supplies industry, we figured it would be a good time to check in with Zacks senior analyst Tom Park. We were looking to see if there are any attractive buys among his coverage....
- External links 2008-08-06
- What's Going On at Roche Palo Alto?
- Derek Lowe submits: I've just been told by a reliable source that something big is up with the Roche (RHHBY.PK)-Palo Alto site. I don't know if this is part of their bid for Genentech DNA or what, but the word "closing" has been mentioned. I hate to pass...
- External links 2008-08-06
- Genentech?s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans
- Ohad Hammer submits: On June 18th, Seattle Genetics SGEN announced it had received a milestone payment from Genentech DNA after the latter filed an IND Investigational New Drug application for an antibody-drug conjugate [ADC] powered by Seattle Genetics’ technology. Intriguingly, there was no additional data about the new agent, nor...
- External links 2008-08-06
- FDA Delivers Another Blow to Amgen?s Anemic Drug Sales
- The Simplified Investor submits: Amgen (NYSE:AMGN) made its reputation as one of the premier firms in the biotechnology industry with its blockbuster anemia drugs, Aranesp and Epogen. Worldwide sales of anemia drugs made up around half of Amgen’s $14.8B revenue in 2007 and an even larger percentage of its...
- External links 2008-08-01
- Icahn Racks Up Gains in ImClone, Motorola, and Amylin
- Lon Juricic submits: Activist investor Carl Icahn had a nice day yesterday. Here's why:Bristol-Myers BMY sent Mr. Icahn a letter presenting a $60 per share offer for ImClone Systems IMCL. Icahn is the Chairman of ImClone, and owns 11,669,544 shares of the biotech company. With shares of ImClone...
- External links 2008-08-01
- Wallstrip: Micrus Endovascular Corp. (MEND)
- Micrus Endovascular Corp. is in the business of prolonging life, and overseas markets appear to be just what the doctor ordered.
- Videos 2008-07-14
- SIGA Technologies: Bioterror Stock Pick
- Jeremy Hellman submits: To quote a story making the rounds Monday: The United States can expect a terrorist attack using nuclear or more likely biological weapons before 2013, reports a bipartisan commission in a study being briefed Tuesday to Vice President-elect Joe Biden. The report suggests...
- External links 2008-12-03
- Short Interests in Pfizer and Dendreon Decline - Is Bearish Sentiment Dissipating?
- Mike Huckman submits: I know that simply pointing this out will draw the ire of certain Pfizer PFE investors who happen to read my blog, but the fact is that PFE is the only major pharmaceutical company whose short interest is big enough to crack the Barron's Top-40. PFE...
- External links 2008-12-03
- Roche Stalling for Time and Money in Genentech Deal
- Derek Lowe submits: Remember back earlier this year, when the temperatures were high, the Dow was at 11,000, and Roche (RHHBY.PK) announced that they wanted to buy the rest of Genentech DNA. So how’s that working out? Not all that well, as far as can be told...
- External links 2008-12-03
- Starting to Rebuild Genoptix
- Trader Mark submits: Genoptix GXDX broke its 200 day moving average just over a week ago after being one of the last holdouts holding above .. .that was at $31. In this market, when you break support, you die a quick death - it's now down to $26. This stock...
- External links 2008-12-03
- Amgen Exceeds Expectations, Again
- Mike Havrilla submits: Shares of Amgen AMGN have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today, Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its...
- External links 2008-10-22
- Earnings Preview: Celgene Corp.
- Celgene Corporation CELG is expected to report Q3 earnings before market open Thursday Oct. 23, with a conference call scheduled for 9:00 am ET. Guidance Analysts are expecting a profit of 39c on revenue of $589M. The consensus range for EPS is 34c to 46c with a revenue range of...
- External links 2008-10-22
- Emergent BioSolutions: Stellar Acting Stock
- Trader Mark submits: I asked readers last week if they had any stocks on their screens that fulfilled some criteria in this quite brutal marketI am curious on your watch lists and holdings if you technical types out there can find stocks over both their 50 and 200 day moving...
- External links 2008-10-22
- Roche: Why No News About Genentech from Earnings Call?
- Mike Huckman submits: Genentech DNA investors who were hoping Roche (RHHBY.PK) would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed. But apparently Roche, which trades on the Swiss...
- External links 2008-10-22
- Earnings Preview: Biogen Idec
- Biogen Idec BIIB is expected to report Q3 earnings Tuesday Oct. 21 before market open, with a conference call scheduled for 8:30 am ET. Guidance Analysts are looking for a profit of 89c on revenue of $1.01B. The consensus is 80c to 95c for EPS, and revenue of $968M to...
- External links 2008-10-20
- Gilead Turns in Sweet Earnings Numbers
- Eben Tessari submits: Gilead GILD put up some pretty sweet numbers this quarter totally blowing away analyst expectations with both revenue and net income up over 25% each. Other high points included a gross profit margin of 84%, prompting some to make the claim that the era of...
- External links 2008-10-19
- Dendreon Gets Another Analyst Thumbs-Down
- Mike Huckman submits: I know I blogged as recently as last week that I thought there wouldn't be much reason to write about Dendreon DNDN for awhile, but I couldn't help myself when I got an email Wednesday night from Merriman Curhan Ford, which is launching coverage of DNDN...
- External links 2008-10-17
- Why It's Time to Buy More Immunogen
- Ohad Hammer submits: Investing, particularly in biotech, comes with plenty of risks and uncertainties. These uncertainties are usually results of clinical trials, which are very unpredictable and unfortunately do not end up well in most cases. Once in a while, a company and its stock price diverge in a way...
- External links 2008-10-17
- Tysabri Concerns Continue to Weigh on Biogen, Elan
- EP Vantage submits: Despite reporting strong quarterly revenues and earnings ahead of Wall Street estimates, shares in Biogen Idec BIIB fell 7% Tuesday and continued to fall in yesterday, down even further to a two-year low of $40.72. With shares in one of Biogen Idec’s key partners, Elan ELN,...
- External links 2008-10-23
- << Previous
- page 1 of 9
- Next >>
Content Types
Refining Tags
- Healthcare (48 results)
- Seeking Alpha (47 results)
- Finance (24 results)
- Eli Lilly & Co. (17 results)
- Pfizer Inc. (15 results)
- ImClone Systems Inc. (15 results)
- Bristol-Myers Squibb Co. (14 results)
- Genentech Inc. (14 results)
- Investment (12 results)
- Biotechnology (11 results)
- Amylin Pharmaceuticals Inc. (11 results)
- china (11 results)
- Financial Accounting (11 results)
- Derek Lowe (10 results)
- Mike Huckman (9 results)
- Operational Accounting (7 results)
- Revenue (7 results)
- Amgen Inc. (7 results)
- Celgene Corp. (7 results)
- Business Operations (6 results)
- ChinaBio Today (6 results)
- Earnings (6 results)
- Trader Mark (6 results)
- GlaxoSmithKline Plc. (6 results)
- EP Vantage (5 results)
- Human Resources (5 results)
- Merck & Co. Inc. (5 results)
- Dendreon Corp. (5 results)
- Biogen Idec Inc. (5 results)
- Emergent Biosolutions (5 results)
- Elan Corp. Plc. (5 results)
- ETF (5 results)
- Wyeth (4 results)
- Novartis AG (4 results)
- theflyonthewall.com (4 results)
- Research & Development (4 results)
- Strategy (4 results)
- Sales (4 results)
- Sales Strategy (4 results)
- Eben Tessari (4 results)
- Mergers & Acquisitions (4 results)
- Management (4 results)
- AstraZeneca Plc. (4 results)
- ImmunoGen Inc. (4 results)
- Cypress Biosciences Inc. (3 results)
- Marketing (3 results)
- Recruitment & Selection (3 results)
- Stock (3 results)
- Alnylam Pharmaceuticals Inc. (3 results)
- Workforce Management (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Dell: Built to fit your business needs.
-
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
- Learn More >>
